Emilia Scalzulli | Ricerc@Sapienza

Pubblicazioni

Titolo	Pubblicato in	Anno
Erythropoietin treatment in chronic phase chronic myeloid leukemia patients treated with frontline imatinib who developed late anemia	EUROPEAN JOURNAL OF HAEMATOLOGY	2020
A Multicenter Real-Life Study On Anticoagulant Treatment With Direct Oral Anticoagulants In Patients With Ph Negative Myeloproliferative Neoplasms	AMERICAN JOURNAL OF HEMATOLOGY	2020
Concomitant Administration of Direct Oral Anticoagulants in Chronic Phase Chronic Myeloid Leukemia Patients Treated with Tyrosine Kinase Inhibitors	CLINICAL DRUG INVESTIGATION	2020
Predictive factors for response and survival in elderly acute myeloid leukemia patients treated with hypomethylating agents: a real-life experience	ANNALS OF HEMATOLOGY	2020
The advantages and risks of ruxolitinib for the treatment of polycythemia vera	EXPERT REVIEW OF HEMATOLOGY	2020
Management of myelofibrosis and concomitant advanced cutaneous squamous cell carcinoma with ruxolitinib associated with cemiplimab	ANNALS OF HEMATOLOGY	2020
Switch from branded to generic imatinib: impact on molecular responses and safety in chronic-phase chronic myeloid leukemia patients	ANNALS OF HEMATOLOGY	2020
Tyrosine kinase inhibitor discontinuation in the management of chronic myeloid leukemia: a critical review of the current practice	EXPERT REVIEW OF HEMATOLOGY	2020
Digital droplet PCR as a predictive tool for successful discontinuation outcome in chronic myeloid leukemia: Is it time to introduce it in the clinical practice?	CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY	2020
Renin angiotensin system inhibitors reduce the incidence of arterial thrombotic events in patients with hypertension and chronic myeloid leukemia treated with second- or third-generation tyrosine kinase inhibitors	ANNALS OF HEMATOLOGY	2020
Low low-density lipoprotein (LDL), cholesterol and triglycerides plasma levels are associated with reduced risk of arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life. ACampus CMLstudy	BLOOD CANCER JOURNAL	2020
Low-dose ponatinib is a good option in chronic myeloid leukemia patients intolerant to previousTKIs	AMERICAN JOURNAL OF HEMATOLOGY	2020
Favorable outcome of chronic myeloid leukemia co-expressing e13a2 and e14a2 transcripts, treated with nilotinib	HEMATOLOGICAL ONCOLOGY	2020
Predictive factors for response and survival in elderly acute myeloid leukemia patients treated with hypomethylating agents: a real-life experience	ANNALS OF HEMATOLOGY	2020
Balanced and unbalanced chromosomal translocations in myelodysplastic syndromes: clinical and prognostic significance	LEUKEMIA & LYMPHOMA	2020
The advantages and risks of ruxolitinib for the treatment of polycythemia vera	EXPERT REVIEW OF HEMATOLOGY	2020
Low Cholesterol, Low-Density Lipoprotein (LDL) and Triglycerides Plasma Levels Are Associated with Lower Risk of Arterial Occlusive Events in Chronic Myeloid Leukemia Patients Treated with Nilotinib	BLOOD	2020
Balanced and unbalanced chromosomal translocations in myelodysplastic syndromes: clinical and prognostic significance	LEUKEMIA & LYMPHOMA	2020
Insights into the optimal use of ponatinib in patients with chronic phase chronic myeloid leukaemia	THERAPEUTIC ADVANCES IN HEMATOLOGY	2019
Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart	HEMATOLOGICAL ONCOLOGY	2019